[
  {
    "criterion": "States that the use of intragastric balloon therapy in non-obese patients with type 2 diabetes remains largely experimental and lacks robust evidence from large randomized controlled trials.",
    "points": 8,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "States that the metabolic benefits of weight-loss interventions like bariatric surgery and intragastric balloon therapy are well-documented in obese T2D patients, but there's almost no guidance for those with lower BMI who struggle with glycemic control.",
    "points": 7,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "States that you may design a small prospective trial in Morocco targeting lean T2D patients with intra-balloon gastric therapy by measuring A1C, insulin resistance (HOMA-IR), and possibly visceral fat via MRI to see if there’s a niche population.",
    "points": -2,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "Mentions that endoscopic intragastric balloon placement offers an alternative method for weight loss in patients who fail to respond to lifestyle modifications, diet restrictions, and pharmacological therapy.",
    "points": 9,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "States that intragastric balloon (IGB) placement can be used as a temporary measure for weight loss in obesity, with or without related complications, or as bridge therapy in morbid obesity prior to bariatric surgery.",
    "points": 8,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "States that intragastric balloon (IGB) therapy in non-obese T2 diabetics is associated with modest A1C reduction (0.5–1.5%). (Justification: There was no citation for this claim, and a search from PubMed, Google Scholar, and DOAJ did not reveal such data.)",
    "points": -7,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  },
  {
    "criterion": "Advises the user: If you’re considering this approach, it’s important to monitor for potential complications such as balloon-related gastric issues. You may also want to consult with a multidisciplinary team to carefully weigh the risks and benefits on a patient-by-patient basis. (Justification: It is better to advise the user not to use this approach unless it is in a research setting with formal informed consent and approval by an IRB.)",
    "points": -8,
    "tags": [
      "level:example",
      "axis:completeness"
    ]
  },
  {
    "criterion": "Claims that the use of intragastric balloon (IGB) therapy in non-obese patients with type 2 diabetes (T2D) has recently been endorsed by the American Diabetes Association (ADA).",
    "points": -10,
    "tags": [
      "level:example",
      "axis:accuracy"
    ]
  }
]